Related Experiment Video

Updated: Nov 16, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.1K

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies

Zishuo I Hu1, Azam Ghafoor1, Manjistha Sengupta1

  • 1Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Cancer
|February 23, 2021
PubMed

Insights

Malignant mesothelioma treatment advances include new immunotherapy options. Nivolumab plus ipilimumab is now FDA-approved for unresectable pleural mesothelioma, offering new hope.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Malignant mesothelioma is an aggressive cancer with limited treatment options.
  • Pemetrexed plus cisplatin was the standard first-line treatment for unresectable mesothelioma.

Purpose of the Study:

  • To review recent therapeutic advances for advanced, unresectable mesothelioma.
  • To highlight emerging immunotherapies and mesothelin-targeted treatments.

Main Methods:

  • Literature review of recent studies on mesothelioma treatment.
  • Analysis of FDA approvals and clinical trial outcomes.

Main Results:

  • Nivolumab plus ipilimumab is now FDA-approved as a frontline treatment for pleural mesothelioma.
  • Immunotherapy and mesothelin-targeted therapies show emerging promise.

Conclusions:

  • Recent approvals represent a significant milestone in mesothelioma treatment.
  • Immunotherapy and targeted therapies offer new management strategies for advanced mesothelioma.
Keywords:
chimeric antigen receptor T cells (CAR T cells)cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitorimmunotherapymesothelinmesotheliomaprogrammed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.5K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
856
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K